Life Sciences Tools and Services
Company Overview of Kailos Genetics, Inc.
Kailos Genetics, Inc., a personalized medicine information company, provides gene-based testing services for clinicians and researchers. It offers TargetRich, a technology that enables analysts to separate genes of interest from unimportant background DNA; Kailos Blue end-to-end software suite; and products for research use and reference lab services. The company also develops carrier screening tests for parents; and tests covering various medical conditions. In addition, it offers its tests for people concerned about health, people starting new medicines, and families planning to have children. The company sells its tests online. Kailos Genetics, Inc. was founded in 2010 and is based in Hun...
601 Genome Way
Huntsville, AL 35806-2908
Founded in 2010
Key Executives for Kailos Genetics, Inc.
Chairman, Chief Executive Officer and President
Chief Financial Officer and Senior Vice President of Corporate Development
Chief Strategy Officer, Treasurer and Director
Chief Scientific Officer, Secretary and Director
Compensation as of Fiscal Year 2017.
Kailos Genetics, Inc. Key Developments
Kailos Genetics Announces Co-Marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research
Mar 21 17
Kailos Genetics announced it has entered into a co-marketing agreement with Illumina, Inc. Under the terms of the agreement, Illumina will market and promote the Kailos TargetRich™ line of research solutions for pharmacogenetics targets through its commercial channels. Kailos research solutions under the agreement include: TargetRich PGxComplete™ and Kailos Blue™. TargetRich PGxComplete™ is a research use-only reagent that targets a spectrum of relevant genes and provides insights on effectiveness of more than 100 medications based on the resulting genotype. Kailos Blue is the company’s automated data analysis solution – built with one of the industry’s most advanced computing – and reporting software for using TargetRich reagents. As an Illumina BaseSpace Suite® ecosystem partner, the solution integrates with and pulls data from BaseSpace Sequence Hub which enables customers to, in real-time, stream their data directly from the sequencing instrument. TargetRich’s automated approach uses a single tube from start to finish with addition-only protocol, which results in a hands-on time of only 75 minutes. The use of unique molecular identifiers offers extremely high levels of sequence quality analysis, delivering results from research experiments at a low cost per targeted base pair.
Kailos Genetics Announces Release of PGxComplet
Oct 14 15
Kailos Genetics announced the release of PGxComplete, a comprehensive, full panel, gene-based test offered at $99 through November 30, 2015, a test that traditionally sells for hundreds or even thousands of dollars. By further reducing their already low cost full panel test, Kailos is able to give consumers greater access to affordable genetic testing, ultimately giving them the power to make more informed decisions about their health. The full panel tests 20 different classes of medications to reveal how one’s body responds to more than 50 types of medications, including antidepressants, opioids, HIV/AIDS treatment and cancer therapy. By understanding how one’s body metabolizes these medicines, each person can take greater control over their own health helping to avoid overdose, select the most effective medications and receive the desired results from treatment. PGxComplete gives people the tools needed to work with their physician to select the right medication and dosage combination based on their DNA. This helps ensure that they are getting the desired effects of treatment. The company developed the PGxComplete test using advanced technology that harnesses DNA sequencing and enables a more holistic view of a person’s gene-based medical information.
Kailos Genetics Hires Cheri Walker as Chief Financial Officer and Senior Vice President of Corporate Development
Jul 27 15
Kailos Genetics, Inc. announced the expansion of its senior management team through the addition of experienced life science industry veteran Cheri Walker, PhD as chief financial officer and senior vice president of corporate development. With more than 18 years of experience in the life science and diagnostic market, Dr. Walker will support Kailos Genetics with a strong combination of technical and financial skills. She will draw on expertise gained from her work as an equity analyst for Deutsche Bank and through senior level corporate development and operating roles at Invitrogen, QIAGEN and Charles River Labs. Dr. Walker also served on the board of directors of Diatherix Laboratories, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 11, 2017
November 16, 2016